Introduction
============

Gastric cancer is the fifth most common malignant tumor in the world and the third most common cause of malignant tumor-related death [@B1]. Though the overall survival (OS) of gastric cancer patients has improved with the development of standardized D2 lymphadenectomy [@B2] and subsequent adjuvant chemotherapy in recent years [@B3], [@B4], the long-term survival rate is still unsatisfactory. Moreover, the majority of gastric cancer patients in China were diagnosed as advanced gastric cancer (AGC) at an early visit. The overall 5-year OS for AGC patients is below 20%, and it is approximately 30% for those who undergo surgery. Even after curative resection, only 30-50% of patients are still alive after 5 years [@B5]. Among AGC T4 gastric cancer patients, which includes tumor perforating serosa (T4a) and invasion of the adjacent structure (T4b), patients often suffered from recurrence and had dismal overall survival, even after R0 resection. Several studies have reported potential prognostic factors affecting the survival of T4 gastric cancer patients after curative resection, including lymph node metastasis, venous invasion, peritoneal washing cytology and tumor diameter[@B6]-[@B8]. However, the sample sizes of previous studies were small.

Recurrence is the most important factor affecting the survival of patients with GC. After curative resection for GC, recurrence patterns include local-regional recurrence, distant lymph node metastasis, hematogenous metastasis, and peritoneum implantation. According to soil and seed theory, T4 GC patients are prone to suffering peritoneal seeding. However, there are few studies exploring the recurrence patterns for T4 GC after curative resection.

In the present study, we aimed to clarify the prognostic factors and recurrence patterns for T4 GC after curative resection, which would help clinicians perform the appropriate treatment in order to improve survival.

Methods and patients
====================

Between January 2004 and December 2014, a total of 249 gastric cancer patients were treated with curative resection (R0 resection) and diagnosed as pathological T4 stage in Sun Yat-sen University Cancer Center. Standardized D2 lymphadenectomy or expanded resections for gastric cancer (including D2 + lymphadenectomy, or D2 lymphadenectomy plus the resection of other adjacent organs) were performed in these patients with curative resection. Tumors were staged according to the seventh edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system [@B9]. Patients were excluded if they received neoadjuvant treatment, were diagnosed as late-stage gastric cancer or underwent R1/2 (microscopically/macroscopically residual tumor) resection. According to NCCN Guidelines [@B10], our clinicians recommended that all the included patients received adjuvant chemotherapy. However, in clinical practice, whether or not they received adjuvant chemotherapy was determined by the will of the patients.

All patients were followed up every 3 months in the first 2 years, 6 months in the 3-5 years, and 12 months annually thereafter, the median follow-up time was 25.87 months (range, 0.3-137).

The following clinicopathological data were collected prospectively through a constructed database: gender, age, tumor size, weight loss, tumor location, type of gastrectomy, extent of lymphadenectomy, intraoperative blood loss, postoperative complications, histological type, harvested lymph nodes, N stage, Lauren type, lymphatic invasion, venous invasion, perineural invasion and adjuvant chemotherapy. OS time was calculated from the time of surgery to death or the last follow-up date. Recurrence patterns were diagnosed based on imaging examination, gastroscopy with biopsy, and/or cytological examination of ascites, or intraoperative findings in patients who underwent reoperation.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 17.0 for Windows (SPSS Inc, Chicago, IL, USA). Categorical variables, presented as rate, were compared by the χ2 (Chi-square) test. Continuous data, expressed as the mean ± standard deviation (SD), were compared by Student\'s t-test. Survival outcomes were analyzed using the Kaplan-Meier method and compared using the log-rank test. Factors that were considered as significant in the univariate analysis (P \< 0.05) were included in the multivariate analysis by Cox regression. HR with 95% confidence intervals (CIs) were presented. P \< 0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

The clinicopathologic characteristics of 249 patients were summarized in Table [1](#T1){ref-type="table"}. There were 221 T4a and 28 T4b GC patients receiving curative resection, comprising 165 males and 84 females, with a mean age of 56.10 years (range, 21-82 years). Some 221 patients underwent standard D2 lymphadenectomy, while 28 patients had expanded resection. The postoperative morbidity rate was 6.0%. A total of 184 patients (73.9%) received adjuvant chemotherapy after surgery. As shown in Table [2](#T2){ref-type="table"}, the main organs invaded with T4b were the pancreas and spleen.

Survival
--------

The median follow-up duration was 25.87 months (range, 0.3-137.0 months). The OS rate of 249 patients was 92.5% at 1 year, 65.3% at 3 years and 46.8% at 5 years (Fig [1](#F1){ref-type="fig"}).

Our results showed that the MST for T4a gastric cancer was longer than that for T4b gastric cancer \[59.47 (95% CI: 32.64-86.30) months versus 25.90 (95% CI: 12.32-39.48) months\] (Fig. [2](#F2){ref-type="fig"}A). The MST difference was significant (P = 0.034). In the univariate analysis, age (P = 0.007) (Fig. [2](#F2){ref-type="fig"}B), weight loss (P = 0.013), tumor location (P\< 0.001) (Fig. [2](#F2){ref-type="fig"}C), extent of lymphadenectomy (P = 0.034), intraoperative blood loss (P \< 0.001) (Fig. [2](#F2){ref-type="fig"}D), postoperative complications (P = 0.038) and N stage (P = 0.012) were significant predictors of OS (Table [3](#T3){ref-type="table"}). Multivariate analysis revealed that age (P = 0.006), tumor location (P \< 0.001) and intraoperative blood loss (P = 0.010) remained as independent prognostic factors for long-term survival (Table [3](#T3){ref-type="table"}).

Pattern of recurrence and risk factors of recurrence
----------------------------------------------------

After a median follow up of 25.87 months, a total of 109 (43.8%) patients experienced recurrence. The recurrence rates for T4a and T4b patients were 92/221 (41.6%) and 17/28 (60.7%), respectively. Of these, the recurrence sites were obtained in a total of 90 patients, with a median of 15.90 (range: 1-71.1) months relapsing after curative surgery. The recurrence patterns were shown in Table [4](#T4){ref-type="table"}. Among those 90 patients, peritoneal metastasis (62.2%) was the most frequent recurrence site, followed by hematogenous metastasis (26.7%), distant lymph node metastasis (24.4%) and locoregional metastasis (15.6%). The peritoneal metastasis was the most common recurrence pattern, accounting for 88.3% (10/12) recurrence in T4b, and 59.0% (46/78) in T4a. The multivariate analysis showed that the N stage and intraoperative blood loss were the independent risk factors for recurrence (Table [5](#T5){ref-type="table"}).

Discussion
==========

Even with the development of standardized D2 lymphadenectomy [@B2] and subsequent adjuvant chemotherapy [@B4], [@B11] for gastric cancer, the survival outcomes are still unsatisfactory, causing a third of cancer-related deaths worldwide [@B1]. Patients often suffer from recurrence after curative resection in the first 5 years, especially T4 patients. Better understanding of the prognostic factors and recurrence patterns for T4 gastric cancer will help clinicians to perform more intensive treatment strategies for high-risk patients. In the present study, our results demonstrated that age, tumor location and intraoperative blood loss were the prognostications of OS for T4 gastric cancer after curative resection. Moreover, peritoneal metastasis was the most common pattern of recurrence.

Several studies [@B6]-[@B8], [@B12], [@B13] had reported the prognostic factors for T4 gastric cancer. Fukuda et al [@B6] reported that number of metastatic lymph nodes, venous invasion and peritoneal washing cytology influenced the prognosis of T4 gastric cancer after potentially curative resection. Li et al [@B7] found that lymph node involvement was the only prognostic factor of OS. However, the sample sizes of previous studies were small, and they included patients with noncurative resection, such as R1/2 resection. While previous studies did not report the survival discrepancy regarding age, our results indicated that elderly patients (\>60 years) had worse survival outcomes. The reasons for this might be considered as follows. First, disorder of immune function in elderly GC patients might relatively weaken antitumor capacity and lead to poor prognosis [@B14]. Second, compared to young patients, elderly patients cannot tolerate extensive lymphadenectomy and the toxicities of chemotherapy. Therefore, elderly patients get inadequate treatment, which affects survival.

The impact of intraoperative blood loss on long-term outcomes had been reported in various types of malignancy [@B15]-[@B18]. Dhar et al [@B19] reported that more than 500 ml blood loss during surgery was an independent predictor of survival in gastric cancer patients with transmural depth invasion following a curative resection. Liang et al [@B20] also found intraoperative blood loss was an independent prognostic factor for gastric cancer after curative resection. In line with previous studies, our results showed that more intraoperative blood loss (\>110 ml) during surgery was an independent prognosis factor in T4 gastric cancer after curative resection. The exact mechanism of how blood loss affects the survival of patients remained unclear. It was considered that excessive intraoperative blood loss reduces the body\'s immunity, thus affecting the patients\' ability to fight cancerous cells [@B19]. Therefore, our results implied that operating carefully to reduce intraoperative blood loss might improve the survival of T4 gastric cancer after curative resection.

In spite of improvements in surgical technique and adjuvant chemotherapy, advanced gastric cancer patients always suffered recurrence after curative resection. The majority of recurrences happened within 2 years postsurgery [@B21]-[@B25]. Previous studies had reported the recurrence patterns of gastric cancer [@B25]-[@B28], especially for patients with tumor invading serosa (T4 stage). However, the recurrence patterns of T4 gastric cancer with curative resection have not been reported. In the present study, 109 of 249 (43.8%) patients experienced relapse. Among them, 90 patients had specifically documented recurrence sites, and peritoneal metastasis was the most frequent recurrence pattern (n = 56), accounting for 62.2% of all relapsed patients. For T4b patients, the peritoneal metastasis ratio reached 88.3%. According to the seed and soil theory, when gastric cancer invades the serosa (T4), the cancer cells have a high possibility of falling into the peritoneal cavity where a suitable environment is provided for the cancer cells to grow. Kondo et al. reported that free cancerous cells could be found in 40% of stage II or III gastric cancers after peritoneal washings [@B29], suggesting that microscopic metastasis still remained after curative resection. Another study also reported that for advanced gastric cancer with serosal involvement, peritoneal metastasis usually occurred, with 15%-50% of patients having peritoneal metastasis at the time of surgery [@B30].

Peritoneal metastasis has been considered the terminal stage of gastric cancer, with a median overall survival of less than 6 months [@B31], accounting for almost 60% of all causes of GC death [@B32]. Therefore, understanding how to prevent and treat peritoneal metastasis is clinically important. In 1988, Fujimoto et al reported that hyperthermic intraperitoneal chemotherapy (HIPEC) was effective for gastric cancer patients with peritoneal seeding. A large number of studies also reported similar results [@B33]-[@B37]. Moreover, several prospective randomized controlled trials [@B38]-[@B41] also reported that curative resection with HIPEC was a useful treatment to prevent occurrence of peritoneal metastasis in advanced gastric cancer. Theoretically, HIPEC after curative resection could help eliminate free cancer cells and micro metastases in the abdominal cavity for T4 gastric cancer, which might prolong survival of patients. Nevertheless, this remained to be confirmed through well-designed randomized controlled trials.

There were several limitations in the present study. First, the present study was a retrospective, single-center research project. Second, the time span of this study was long (10 years). Therefore, the results of this study should be interpreted cautiously. A large-scale, validation study is required to confirm the results.

Conclusions
===========

For T4 gastric cancer patients after curative resection, older age, entire gastric cancer and more intraoperative blood loss were associated with poor OS. The recurrence rate after curative resection for T4 was high, and the most common recurrence pattern was peritoneal metastasis.

![Kaplan-Meier survival curves of 249 T4 gastric cancer patients after curative resection.](jcav10p1181g001){#F1}

![Kaplan-Meier survival curves of T4 gastric cancer patients after curative resection according to tumor invasion (T4a vs. T4b) (P = 0.034) (A), age (P = 0.007) (B), tumor location (P \< 0.001) (C), intraoperative blood loss (P \< 0.001) (D). All P-values were calculated using the log-rank test.](jcav10p1181g002){#F2}

###### 

Clinicopathologic characteristics for 249 patients with T4 gastric cancer after curative resection.

  Variables                         n (%)
  --------------------------------- ------------
  Gender                            
  Male                              165 (66.3)
  Female                            84 (33.7)
  Age (y)                           
  ≤60                               156 (62.7)
  \>60                              93 (37.3)
  Tumor diameter (cm)               
  ≤6.5                              176 (70.7)
  \>6.5                             73 (29.3)
  Weight loss (kg)                  
  ≤5                                197 (79.1)
  \>5                               52 (20.9)
  Location of tumor                 
  Upper 1/3                         93 (37.3)
  Middle 1/3                        38 (15.3)
  Lower 1/3                         97 (39.0)
  Entire                            21 (8.4)
  Type of gastrectomy               
  Distal                            103 (41.4)
  Proximal                          47 (18.9)
  Total                             99 (39.7)
  Lymphadenectomy                   
  D2                                221 (88.8)
  Expanded D2                       28 (11.2)
  Intraoperative blood loss (ml)    
  ≤110                              142 (57.0)
  \>110                             107 (43.0)
  Postoperative complications       
  Absence                           234 (94.0)
  Presence                          15 (6.0)
  Histological type                 
  Moderate or well differentiated   26 (10.4)
  Poorly differentiated             223 (89.6)
  Number of harvested lymph nodes   
  \<15                              21 (8.4)
  ≥15                               228 (91.6)
  N stage                           
  N0-N1                             77 (30.9)
  N2-N3                             172 (69.1)
  Lauren classification             
  Intestinal                        99 (39.8)
  Diffuse                           25 (10.0)
  Mixed                             38 (15.2)
  Lymphatic invasion                
  Absence                           138 (55.4)
  Presence                          111 (44.6)
  Venous invasion                   
  Absence                           151 (60.6)
  Presence                          98 (39.4)
  Perineural invasion               
  Absence                           113 (45.4)
  Presence                          136 (54.6)
  Postoperative chemotherapy        
  No                                65 (26.1)
  Yes                               184 (73.9)

###### 

Organs Invaded by T4b Gastric Cancer.

  Invaded organs                  n    \%
  ------------------------------- ---- ------
  Pancreas                        15   53.6
  Spleen                          13   46.4
  Liver                           4    14.3
  Transverse colon or mesocolon   3    10.7
  Adrenal gland                   2    7.2
  Gallbladder                     1    3.6
  Diaphragm                       1    3.6
  No. of invaded organs                
  One                             20   71.4
  Two                             6    21.4
  Four                            2    7.2

###### 

Univariate analysis of risk factors and Multivariable Cox regression analysis of risk factors for patients with T4 gastric cancer.

  ----------------------------------------------------------------------------------------------------------------
  Variables                         Univariate analysis                                    Multivariate analysis
  --------------------------------- ---------------------- ------- ----------------------- -----------------------
  Gender                                                   0.555                           

  Male                              1                                                      

  Female                            1.144 (0.732\~1.787)                                   

  Age (y)                           1                      0.007                           0.006

  ≤60                               1.769 (1.160\~2.697)           1                       

  \>60                                                             1.859 (1.195\~2.892)    

  Tumor diameter (cm)                                      0.026                           0.561

  ≤6.5                              1                              1                       

  \>6.5                             1.622 (1.055\~2.494)           0.844 (0.477\~1.494)    

  Weight loss (kg)                                         0.013                           0.067

  ≤5                                1                              1                       

  \>5                               1.785 (1.120\~2.844)           1.593 (0.968\~2.623)    

  Location of tumor                                        0.000                           0.000

  Upper 1/3                         1                              1                       

  Middle 1/3                        1.016 (0.526\~1.963)           1.252 (0.626\~2.503)    

  Lower 1/3                         0.966 (0.585\~1.593)           0.899 (0.537\~1.506)    

  Entire                            4.854 (2.463\~9.567)           5.640 (2.463\~12.915)   

  Type of gastrectomy                                      0.204                           

  Proximal                          1                                                      

  Distal                            1.195 (0.682\~2.094)                                   

  Total                             1.535 (0.954\~2.468)                                   

  Lymphadenectomy                                          0.034                           0.819

  D2                                1                              1                       

  Expanded D2                       1.801 (1.037\~3.125)           1.072 (0.588\~1.955)    

  Intraoperative blood loss (ml)                           0.000                           0.010

  ≤110                              1                              1                       

  \>110                             2.148 (1.392\~3.316)           1.851 (1.162\~2.950)    

  Postoperative complications                              0.038                           0.223

  Absence                           1                              1                       

  Presence                          2.130 (1.027\~4.420)           1.606 (0.750\~3.439)    

  Histological type                                        0.913                           

  Moderate or well\                 1                                                      
  differentiated                                                                           

  Poorly differentiated             1.037 (0.536\~2.007)                                   

  Number of harvested lymph nodes                          0.156                           

  ≤15                               1                                                      

  \>15                              0.663 (0.374\~1.175)                                   

  N stage                                                  0.012                           0.113

  N0-N1                             1                              1                       

  N2-N3                             1.874 (1.137\~3.089)           1.520 (0.906\~2.551)    

  Lauren classification                                    0.849                           

  Intestinal                        1                                                      

  Diffuse                           0.896 (0.370\~2.173)                                   

  Mixed                             0.790 (0.344\~1.816)                                   

  Lymphatic invasion                                       0.082                           

  Absence                           1                                                      

  Presence                          1.458 (0.951\~2.235)                                   

  Venous invasion                                          0.923                           

  Absence                           1                                                      

  Presence                          1.023 (0.644\~1.625)                                   

  Perineural invasion                                      0.549                           

  Absence                           1                                                      

  Presence                          0.871 (0.555\~1.368)                                   

  Postoperative chemotherapy                               0.272                           

  No                                1                                                      

  Yes                               0.760 (0.465\~1.242)                                   

  T4 stage                                                 0.034                           

  T4a                               1                                                      

  T4b                               1.801 (1.037\~3.125)                                   
  ----------------------------------------------------------------------------------------------------------------

###### 

Sites of recurrence in 90 patients.

  Recurrence site         Total group (%)   T4a   T4b   P value
  ----------------------- ----------------- ----- ----- ---------
  peritoneum implanting   56 (62.2)         46    10    0.105
  Hematogenous            24 (26.7)         21    3     0.888
  distant lymph node      22 (24.4)         20    2     0.501
  Locoregional            14 (15.6)         14    0     0.110
  No. of sites                                          
  One                     67 (74.4)                     
  Two                     19 (21.1)                     
  Three                   4 (4.5)                       

###### 

Relationship between the recurrence and clinicopathologic characteristics by univariate and multivariable analysis in T4 gastric cancer patients after curative resection.

  Variables                         Univariate analysis             χ^2^test                          Multivariate analysis
  --------------------------------- --------------------- --------- ---------- ---------------------- -----------------------
  No. of patients                   (n=140)               (n=109)                                     
  Gender                                                            0.835                             
  Male                              48                    36                                          
  Female                            92                    73                                          
  Age (y)                                                           0.385                             
  ≤60                               91                    65                                          
  \>60                              49                    44                                          
  Tumor diameter (cm)                                               0.090                             
  ≤6.5                              105                   71                                          
  \>6.5                             35                    38                                          
  Weight loss (kg)                                                  0.050                             
  ≤5                                117                   80                                          
  \>5                               23                    29                                          
  Location of tumor                                                 0.115                             
  Upper 1/3                         58                    35                                          
  Middle 1/3                        21                    17                                          
  Lower 1/3                         54                    43                                          
  Entire                            7                     14                                          
  Type of gastrectomy                                               0.291                             
  Proximal                          58                    45                                          
  Distal                            22                    25                                          
  Total                             60                    39                                          
  Lymphadenectomy                                                   0.055                             
  D2                                129                   92                                          
  Expanded D2                       11                    17                                          
  Intraoperative blood loss (ml)                                    0.004                             0.041
  ≤110                              91                    51                   1                      
  \>110                             49                    58                   1.778 (1.024\~3.088)   
  Postoperative complications                                       0.191                             
  Absence                           134                   100                                         
  Presence                          6                     9                                           
  Histological type                                                 0.796                             
  Moderate or well differentiated   14                    12                                          
  Poorly differentiated             126                   97                                          
  Number of harvested lymph nodes                                   0.359                             
  ≤15                               14                    15                                          
  \>15                              126                   94                                          
  N stage                                                           0.016                             0.019
  N0-N1                             52                    25                   1                      
  N2-N3                             88                    84                   1.992 (1.119\~3.545)   
  Lauren classification                                             0.308                             
  Intestinal                        59                    40                                          
  Diffuse                           16                    9                                           
  Mixed                             28                    10                                          
  Lymphatic invasion                                                0.879                             
  Absence                           77                    61                                          
  Presence                          63                    48                                          
  Venous invasion                                                   0.308                             
  Absence                           81                    70                                          
  Presence                          59                    39                                          
  Perineural invasion                                               0.029                             0.139
  Absence                           55                    58                   1                      
  Presence                          85                    51                   0.659 (0.379\~1.145)   
  Postoperative chemotherapy                                        0.315                             
  No                                40                    25                                          
  Yes                               100                   84                                          
  T4 stage                                                          0.055                             
  T4a                               128                   92                                          
  T4b                               11                    17                                          

[^1]: ^\#^ These authors contributed equally to this study.

[^2]: ^\*^ These authors also contributed equally to this study.

[^3]: Competing Interests: The authors have declared that no competing interest exists.
